These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38853023)

  • 1. Fibulin-4 as a potential extracellular vesicle marker of fibrosis in patients with cirrhosis.
    Kumagai M; Tsuchiya A; Yang Y; Takeda N; Natsui K; Natusi Y; Tomiyoshi K; Yamazaki F; Koseki Y; Shinchi H; Imawaka N; Ukekawa R; Nishibu T; Abe H; Sasaki T; Ueda K; Terai S
    FEBS Open Bio; 2024 Aug; 14(8):1264-1276. PubMed ID: 38853023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.
    Sakane S; Hikita H; Shirai K; Sakamoto T; Narumi R; Adachi J; Kakita N; Yamada Y; Toyoda H; Takahashi H; Suda G; Kai M; Tahata Y; Sakamori R; Kumazaki S; Fukumoto K; Myojin Y; Murai K; Kodama T; Tatsumi T; Tomonaga T; Sakamoto N; Morii E; Takehara T
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38829196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of small extracellular vesicle proteins from human serum for liver cirrhosis and liver cancer.
    Uzzaman A; Zhang X; Qiao Z; Zhan H; Sohail A; Wahid A; Shang Z; Guan X; Cao CX; Xiao H
    Biochimie; 2020 Oct; 177():132-141. PubMed ID: 32835735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of disease-associated protein expression using quantitative proteomics—fibulin-5 is expressed in association with hepatic fibrosis.
    Bracht T; Schweinsberg V; Trippler M; Kohl M; Ahrens M; Padden J; Naboulsi W; Barkovits K; Megger DA; Eisenacher M; Borchers CH; Schlaak JF; Hoffmann AC; Weber F; Baba HA; Meyer HE; Sitek B
    J Proteome Res; 2015 May; 14(5):2278-86. PubMed ID: 25807371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood reelin in the progression of chronic liver disease.
    Sturm L; Roth L; Zoldan K; Schultheiss M; Boettler T; Huber JP; Kaeser R; Thimme R; Bettinger D
    Adv Med Sci; 2021 Mar; 66(1):148-154. PubMed ID: 33561810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review.
    Yao M; Wang L; Leung PSC; Li Y; Liu S; Wang L; Guo X; Zhou G; Yan Y; Guan G; Chen X; Bowlus CL; Liu T; Jia J; Gershwin ME; Ma X; Zhao J; Lu F
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):282-294. PubMed ID: 29256057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles.
    Seo W; Gao Y; He Y; Sun J; Xu H; Feng D; Park SH; Cho YE; Guillot A; Ren T; Wu R; Wang J; Kim SJ; Hwang S; Liangpunsakul S; Yang Y; Niu J; Gao B
    J Hepatol; 2019 Nov; 71(5):1000-1011. PubMed ID: 31279903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular Vesicles as Delivery Vehicles for Non-Coding RNAs: Potential Biomarkers for Chronic Liver Diseases.
    Ferro A; Saccu G; Mattivi S; Gaido A; Herrera Sanchez MB; Haque S; Silengo L; Altruda F; Durazzo M; Fagoonee S
    Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of candidate biomarkers from plasma-derived extracellular vesicles of patients with cirrhosis and hepatocellular carcinoma: an exploratory proteomic study.
    Zertuche-Martínez C; Velázquez-Enríquez JM; González-García K; Santos-Álvarez JC; Romero-Tlalolini MLÁ; Pina-Canseco S; Pérez-Campos Mayoral L; Muriel P; Villa-Treviño S; Baltiérrez-Hoyos R; Arellanes-Robledo J; Vásquez-Garzón VR
    Mol Omics; 2024 Aug; 20(7):483-495. PubMed ID: 39011654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
    Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
    BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of novel biomarkers of liver cirrhosis by proteomic analysis.
    Mölleken C; Sitek B; Henkel C; Poschmann G; Sipos B; Wiese S; Warscheid B; Broelsch C; Reiser M; Friedman SL; Tornøe I; Schlosser A; Klöppel G; Schmiegel W; Meyer HE; Holmskov U; Stühler K
    Hepatology; 2009 Apr; 49(4):1257-66. PubMed ID: 19177598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.
    Motawi TK; Shaker OG; El-Maraghy SA; Senousy MA
    PLoS One; 2015; 10(9):e0137706. PubMed ID: 26352740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wisteria floribunda agglutinin-positive human Mac-2 binding protein in decompensated cirrhosis.
    Uojima H; Hidaka H; Tanaka Y; Inoue T; Onoue M; Wada N; Kubota K; Nakazawa T; Shibuya A; Fujikawa T; Nakayama T; Yamanoue H; Sung JH; Kako M; Koizumi W
    J Gastroenterol Hepatol; 2018 Nov; 33(11):1889-1896. PubMed ID: 29737582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension.
    Lisotti A; Azzaroli F; Cucchetti A; Buonfiglioli F; Cecinato P; Calvanese C; Simoni P; Arena R; Montagnani M; Golfieri R; Colecchia A; Festi D; Mazzella G
    Liver Int; 2016 Sep; 36(9):1313-21. PubMed ID: 26786880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic analysis of small extracellular vesicles from the plasma of patients with hepatocellular carcinoma.
    Dong W; Xia Z; Chai Z; Qiu Z; Wang X; Yang Z; Wang J; Zhang T; Zhang Q; Jin J
    World J Surg Oncol; 2022 Dec; 20(1):387. PubMed ID: 36471393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.
    Göbel T; Vorderwülbecke S; Hauck K; Fey H; Häussinger D; Erhardt A
    World J Gastroenterol; 2006 Dec; 12(47):7604-12. PubMed ID: 17171788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
    Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
    Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection.
    Gressner OA; Fang M; Li H; Lu LG; Gressner AM; Gao CF
    Clin Chim Acta; 2013 Jun; 421():126-31. PubMed ID: 23501329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild hyperbilirubinemia as a marker of oesophageal varices in HCV-related compensated cirrhotic patients.
    Mikuła T; Suchacz MM; Stańczak W; Jabłońska J; Kozłowska J; Cybula A; Cianciara J; Wiercińska-Drapało A
    Pol Merkur Lekarski; 2019 May; 46(275):209-212. PubMed ID: 31152532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.